Recently new evidence about fibroblast growth factor 21 (FGF21) highlights the
opportunities to use this molecule in new pharmaceutical formulations to combat type 2 …

Objective: HIV-1-infected patients with lipodystrophy show insulin resistance, dyslipidemia
and other signs of metabolic syndrome. Fibroblast growth factor-21 (FGF21) is a novel …

Background Fibroblast growth factor (FGF)-21 is a novel regulator of glucose and lipid
metabolism. Recently, increased FGF-21 mRNA expression in muscle was found in patients …

Objective Patients with lipodystrophy (LD) suffer from loss of subcutaneous adipose tissue
accompanied by dysregulation of several adipocyte-secreted factors. However, regulation of …

Background Antiretroviral therapy has significantly improved prognosis in treatment against
HIV infection, however, prolonged exposure is associated to cardiovascular diseases …

Background: Fibroblast Growth Factor 21 (FGF21) serum levels are associated with insulin
resistance and metabolic syndrome in HIV patients. Objective: To quantify FGF21 levels in …

Background Fibroblast growth factor-21 (FGF21) has emerged as an important regulator of
glucose, lipid, and body weight homeostasis. However, recent experimental studies have …

Fibroblast growth factor 21 (FGF21) is a circulating peptide hormone primarily synthesized
by the liver, and to a lesser extent, by skeletal muscle, adipose tissue, and pancreas. 1, 2 Its …

Background: To determine the role of fibroblast growth factor (FGF)-19 and FGF21 and the
endocrine FGFs receptor system in the metabolic alterations that manifest in HIV-1–infected …

Objectives Dyslipidaemia, insulin resistance, metabolic syndrome and HIV/HAART-
associated lipodystrophy syndrome (HALS) are common comorbidities in HIV-1-infected …